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Abstract
Background Cancer screening is a behavior that represents
investment in future health. Such investment may depend on
how much ‘future’ a person expects.
Purpose The purpose of this study was to investigate the pro-
spective association between perceived personal life expec-
tancy and participation in fecal occult blood test screening
for colorectal cancer (CRC) in a national program.
Methods Data were from interviews with 3975 men and
women in the English Longitudinal Study of Ageing
(ELSA) within the eligible age range for the national screen-
ing program (60 to 74 years). Perceived life expectancy was
indexed as the individual’s estimate of their chance of living
another 10–15 years (exact time varied by age), assessed in
2008/2009. Participation in CRC screening from 2010 to
2012/2013 was assessed in 2012/2013. Logistic regression
was used to estimate the association between perceived life
expectancy and screening participation, adjusted for numer-
acy and known mortality risk factors.
Results Overall, 71% of respondents (2817/3975) reported
completing at least one fecal occult blood test (FOBt) during
the follow-up. Screening uptake was 76% (1272/1683) among
those who estimated their 10–15-year life expectancy as 75–
100%, compared with 52% (126/243) among those who esti-
mated theirs as 0–25% (adjusted OR 1.74, 95% CI 1.29–
2.34).
Conclusions A longer perceived life expectancy is associated
with greater likelihood of participating in CRC screening in
England. However, half of people with a low perceived life
expectancy still participated in screening. Given that CRC
screening is recommended for adults with a remaining life
expectancy of ≥10 years, future research should investigate
how to communicate the aims of screening more effectively.
Keywords Colorectal cancer .Cancer screening .Fecaloccult
blood test . Perceived life expectancy . Behavioral economics
Introduction
Colorectal cancer (CRC) is the third most common can-
cer in men and the second most common cancer in
women worldwide, with an estimated 1.4 million cases
and 693,300 deaths in 2012 [1]. The highest incidence
rates are in developed countries, many of which have
screening tests available through opportunistic or orga-
nized programs [2]. In the UK, the National Health
Service (NHS) provides CRC screening without charge
using the fecal occult blood test (FOBt), which is
mailed biennially to the home addresses of all men
and women aged 60–74 years. Although the NHS
Bowel Cancer Screening Programme was one of the
first organized CRC screening programs worldwide, the
UK lags behind other countries internationally in CRC
outcomes, making effective screening an important pub-
lic health priority [3]. However, screening uptake is low,
with just over 50% of eligible adults participating in
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any biennial screening round. In other countries where
FOBt screening is offered, uptake also tends to be low
[2]. Because routine screening improves CRC outcomes
and reduces mortality in the population [4, 5], a better
understanding of the causes of low uptake is needed to
inform sys tem- leve l in te rven t ions to increase
participation.
A potentially salient factor in explaining cancer screening
uptake that has been previously overlooked is perceived life
expectancy (PLE). Participation in cancer screening repre-
sents an investment in future health. Screening participants
undergo the immediate burden of completing a screening test
in the hope of protecting their future health and survival
through a negative result or an early diagnosis of cancer.
This perspective on health, as a form of human capital that
depreciates with time and can be invested in through behav-
iors such as cancer screening, forms the basis of the theory of
health as human capital [6–8]. PLE estimates are informed by
knowledge that people have readily at hand that may not al-
ways be queried about in study questionnaires, such as a more
complete range of personal health and risk behaviors. PLE is
predictive of actual mortality in American adults aged 50 and
over in the US Health and Retirement Study across 2- and 8-
year follow-up periods [9, 10]. The utility of PLE for
predicting future behavior and actual mortality risk has been
advocated for in the economic literature [11].
It is important to understand the nature of any poten-
tial association between PLE and CRC screening up-
take, as the American College of Physicians does not
recommend cancer screening for adults who have a re-
maining life expectancy of less than 10 years [12]. PLE
could therefore be a useful factor that people may take
into account when making informed decisions about
cancer screening, but little is known about the degree
to which it influences these decisions. Previously, PLE
has been positively associated with uptake of mammog-
raphy screening for breast cancer in the European
Survey of Health, Ageing, and Retirement (SHARE),
where women who expected to live longer were more
likely to take up screening than those with low expec-
tations of their future longevity [13]. The prospective
association between PLE and participation in CRC
screening through a nationally organized screening pro-
gram is unknown.
We aimed to investigate the prospective association be-
tween perceived life expectancy, indexed as an individual’s
own estimate of their chance of living another 10–15 years
in 2008/2009, and participation in CRC screening through
England’s NHS Bowel Cancer Screening Programme from
2010 to 2012/2013. We hypothesized that participation in
CRC screening, a form of future health investment, would
be higher among those with higher self-perceived remaining
life expectancy.
Materials and Methods
Sample
The English Longitudinal Study of Ageing (ELSA) is a
population-based cohort study of English men and women
aged ≥50 years [14]. The ELSA cohort was established in
2002 and is based on a random stratified sample of English
households [14]. The “core” ELSA sample consists of respon-
dents recruited in the original 2002 sample (n = 12,100; re-
sponse rate = 66%) and newer respondents recruited at subse-
quent waves of data collection to account for the aging struc-
ture of the original sample. ELSA data are collected in bien-
nial “waves” through computer-assisted in-person interviews
in the study respondents’ homes.
The present analysis uses data from waves 4 (2008/2009)
and 6 (2012/2013) of the ELSA data collection. Perceived life
expectancy was assessed in the study interview in 2008/2009
(wave 4; “baseline”), and completion of at least one FOBt
through the NHS Bowel Cancer Screening Programme from
2010 to 2012/2013 was assessed in the study interview in
2012/2013 (wave 6; ‘follow-up’). Eligible respondents for this
analysis were core ELSA sample members who were aged
60–74 years at the follow-up (i.e., within the FOBt
screening-eligible age range) with non-proxy study inter-
views. Proxy interviews with a family member or friend were
conducted if the respondent was cognitively impaired or insti-
tutionalized. Of the 9896 core ELSA sample members in
2008/2009, 300 had a proxy interview and were excluded,
leaving 9596 potentially eligible participants. Of these, 7704
were retained in 2012/2013, giving an 80% retention rate over
the 4-year follow-up period. Of these, 187 had a proxy inter-
view at wave 6 and a further 3200 were outside of the eligible
age range for FOBt screening. In total, the eligible sample for
this analysis comprised 4315 men and women (Fig. 1).
Ethical Approval and Participant Consent
The ELSAwas approved by the LondonMulticentre Research
Ethics Committee (MREC/01/2/91), and informed consent
was obtained from all participants.
Measures
Perceived life expectancy was assessed in the study interview
by the question, “What are the chances (from 0%-100%) you
will live to be age X or more?” Xwas defined as follows: if the
participant was age 65 or under, X = 75; if age 66–69, X = 80;
and if age 70–74, X = 85. The participants were presented with
a show card displaying a scale from 0 to 100 to aid their
responses.
Uptake of FOBt-based CRC screening in England’s NHS
Bowel Cancer Screening Programme was assessed in the
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study interview by the question, “Have you ever completed a
home testing kit for screening bowel cancer?” (yes, no). Those
who responded “yes” were then asked, “How long ago was
your most recent test?” (month, year), and “Was this test part
of the NHS Bowel Cancer Screening Programme?” (yes, no).
Those who responded that their most recent test was prior to
2010 were coded as “no” for uptake of screening over the
study follow-up (n = 151; a small number as the screening
program was not fully implemented nation-wide until 2010).
Another small number reported that their test was not part of
the screening program (n = 54). Self-reported uptake of FOBt
in the context of England’s national program has recently been
shown in a similar population-based sample to be valid against
NHS uptake records, with 94.2% agreement and κ = 0.74
[15].
Covariates assessed in the study interview that are known
to be, or are plausibly, associated with one or both of PLE and
CRC screening were age (continuous), sex, educational attain-
ment (post-secondary degree or equivalent; up to a post-
secondary degree; no qualifications [including no high school
qualification]), ethnicity (white; non-white), marital status
(married or living as married; single), smoking status (never;
former; current), self-rated health (excellent; very good; good;
fair; poor), and previously having had a diagnosis of cancer,
cardiovascular disease, or high blood pressure (no; yes). Ages
of mother and father currently or at death (continuous; per
10 years) were included as a proxy for health endowment, as
people may predict their own life expectancies informed by
those of their parents [13].
Because PLE is on a numeric scale, numeracy was mea-
sured in the study interview using six basic questions such as,
‘If the chance of getting a disease is 10 percent, how many
people out of 1,000 (one thousand) would be expected to get
the disease?” (answer options: 100; 10; 90; 900). Each ques-
tion was scored as correct or incorrect, and they were summed
to give a total score out of six. The continuous numeracy score
was included in this analysis, to account for any numeracy
difficulties that might affect response to the PLE question.
Statistical Analysis
PLE was categorized into low (<25%), middle low (25–49%),
middle high (50–74%), and high (≥75%) chance of surviving
another 10–15 years. This categorization had the advantage of
smoothing out focal points in responses and therefore reduc-
ing the likelihood of focal response bias in the results. The
focal response bias is a cognitive bias, where people will
round a continuous numerical estimate to the nearest whole
number (in this case, at intervals of 10 on a scale of 0 to 100),
rather than responding on a truly continuous scale, as the
probability of survival should be in reality [11, 16]. The most
common focal points we observed were at 50, 80, and 70%,
with smaller spikes seen at other 10-year intervals, consistent
with PLE data observed elsewhere [13].
Characteristics of the sample (PLE and covariates) were
described according to FOBt uptake status (defined as yes
vs. no for completion of at least one FOBt over the follow-
up period). Means and standard deviations for continuous var-
iables were compared across FOBt uptake status using the
Wilcoxon rank-sum test. Frequency counts for categorical var-
iables were compared across FOBt uptake status using the chi-
squared test. Logistic regression was used to estimate odds
ratios (ORs) and 95% confidence intervals (CIs) for the pro-
spective association between PLE and FOBt uptake status.
Both unadjusted and fully adjusted models including all co-
variates were estimated. The final analytical sample contained
n = 3975 participants, as 39 (<1%) were missing data on PLE,
8 (<1%) on education, 1 (<1%) on ethnicity, 2 (<1%) on self-
rated health, 132 (3%) on mother’s age currently or at death,
233 (5%) on father’s age currently or at death, and 12 (<1%)
on numeracy.
To examine the accuracy of PLE, we compared PLE re-
sponses with objectively estimated 10-year mortality risk ac-
cording to the ELSA Mortality Risk Index [17]. The ELSA
Mortality Risk Index was developed and validated in the base-
line ELSA sample and is harmonized with a similar index
developed for the US Health and Retirement Study (HRS)
[18, 19]. The ELSA Mortality Risk Index assigns a risk score
to individuals based on age, sex, comorbid conditions (cancer,
lung disease, and heart failure), smoking status, level of phys-
ical activity, and difficulty with functional tasks (preparing a
hot meal, walking 100 yards, and pushing and pulling large
objects). The risk scores correspond to a 10-year risk for all-
cause mortality [17]. We compared mean PLE estimates
across the risk scores. To assess the relationship between
Fig. 1 Study eligibility flow
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PLE and FOBt screening independently of estimated 10-year
mortality risk, the fully adjusted model from above was addi-
tionally adjusted for ELSA Mortality Index score and the co-
variates that were not included within the index (education,
ethnicity, marital status, self-rated health, numeracy, and ages
of mother and father currently or at death).
Sensitivity analyses were performed removing those who
reported completing an FOBt kit outside of the national pro-
gram (n = 54) and removing those who reported that their
most recent FOBt was prior to 2010 (n = 151). We also re-
stricted the analysis to those whose PLE estimates were 10 to
11 years in the future, rather than 10 to 15 years into the future,
to examine whether the prediction timespan affected the re-
sults. All analyses were conducted at the 95% confidence
level using StataSE 13.1 (College Station, Texas).
Results
Table 1 shows the baseline characteristics of participants.
Grouping the PLE responses, 6% of participants (243/3975)
estimated their chance of living another 10–15 years as 0–
24%, 8% (312/3975) estimated a 25–49% chance, 44%
(1737/3975) estimated a 50–74% chance, and 42%
(1683/3975) estimated a 75–100% chance. The mean age at
baseline was 62.6 years (SD 4.1). Just over half of participants
were female (55%; 2174/3975). Nearly one third had post-
secondary degree education (29%; 1152/3975) and 22% had
no educational qualifications (885/3975). Only 2% of the sam-
ple was not white (88/3975). Most participants were married
or living as married (77%; 3071/3975). On average, the age of
mother currently or at death was 78 years (SD 12), and the age
of father currently or at death was 72 years (SD 13). Smoking
status, self-rated health, and chronic disease diagnoses are also
shown in Table 1.
Table 1 also shows the baseline characteristics of partici-
pants according to FOBt uptake status over the follow-up. Just
over two thirds of participants (71%; 2817/3975) reported
completing at least one FOBt over the follow-up. FOBt uptake
greatly differed across PLE categories, with 52% (126/243) of
participants who estimated a 0–24% PLE having completed
the test compared to 76% (1272/1683) of those who estimated
a 75–100% PLE (p < 0.0001). Most other covariates were, as
predicted, significantly positively associated with FOBt up-
take over the study follow-up period, including having an
older age of either mother or father currently or at death and
having a higher score on the numeracy assessment (Table 1).
Adjusted analyses are therefore essential to examine the inde-
pendent prospective association between PLE and FOBt up-
take. Having a previous cancer diagnosis was not associated
with FOBt uptake over the follow-up.
In the fully adjusted model (Table 2), PLE was associated
with FOBt uptake in a statistically significant linear dose-
response fashion (ptrend < 0.0001), with the following ORs
predicting FOBt uptake (yes vs. no): OR = 1.32 (95% CI
0.93–1.88) for 25–49%, OR = 1.52 (95% CI 1.14–2.03) for
50–74%, and OR = 1.74 (95%CI 1.29–2.34) for 75–100%, all
vs. 0–24% (Table 2). Older age was negatively associatedwith
FOBt uptake (OR = 0.96; 95% CI 0.95–0.98 per year), as was
having no educational qualifications (OR = 0.79; 95% CI
0.64–0.98 vs. degree level education), being single
(OR = 0.72; 95% CI 0.61–0.84 vs. married or living as mar-
ried), being a current smoker (OR = 0.52; 95% CI 0.42–0.65),
and having poor self-rated health (OR = 0.64; 95% CI 0.44–
0.92; Table 2). Being female was positively associated with
FOBt uptake (OR = 1.30; 95% CI 1.12–1.51), as was having
better numeracy (OR = 1.06; 95% CI 1.00–1.13 per point out
of 6; Table 2). In the model adjusted for continuous ELSA
Mortality Risk Index score and covariates, the relationship
between PLE and FOBt screening became slightly stronger
than in the previous ORs: OR = 1.35 (95% CI 0.93–1.88)
for 25–49%, OR = 1.56 (95% CI 1.18–2.08) for 50–74%,
and OR = 1.81 (95% CI 1.35–2.43) for 75–100%, all vs. 0–
24% (Table 2). Independently of PLE and covariates, higher
10-year mortality risk according to the Index was associated
with lower odds of participating in FOBt screening
(OR = 0.91; 95% CI 0.88–0.94 per point increase; Table 2).
Table 3 shows the mean PLE estimates across each scoring
point on the ELSAMortality Risk Index. The continuous PLE
estimates decreased linearly as ELSA Index scores increased,
with a correlation of moderate strength (Pearson’s r = −0.27;
p < 0.0001). In this study, the ELSA Index scores ranged from
1 point (lowest mortality risk, corresponding to a 10-year
mortality rate of 3% in the development study) to 18 points
(highest mortality risk, corresponding to a 10-year mortality
rate of 95% in the development study). In those who scored 1
point on the ELSA Index, the mean self-reported chance of
living another 10–15 years was 73.6% (SD 17.9%). In those
who scored 12 or more points on the ELSA Index, the mean
self-reported chance of living another 10–15 years was 46.4%
(SD 27.4%).
The main results were not affected in the sensitivity analy-
ses excluding from the fully adjusted model each of the 54
participants who reported completing the FOBt outside the
national screening program (OR = 1.31; 95% CI 0.92–1.87
for 25–49%, OR = 1.48; 95% CI 1.11–1.97 for 50–74%,
OR = 1.69; 95% CI 1.26–2.29 for 75–100%, all vs. 0–24%)
and the 151 participants who reported completing FOBt
screening prior to the study period (OR = 1.40; 95% CI
0.97–2.03 for 25–49%, OR = 1.53; 95% CI 1.13–2.06 for
50–74%, OR = 1.76; 95% CI 1.29–2.40 for 75–100%, all
vs. 0–24%). Restricting the analysis to those whose
PLE estimates ranged from 10 to 11 years, rather than
10 to 15 years, as in the full sample, resulted in a
slightly stronger magnitude of association between PLE
and screening uptake (not shown).
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Table 1 Baseline sample
characteristics, overall and
according to FOBt screening, The
English Longitudinal Study of
Ageing, 2008–13, n = 3975
Baseline characteristic Overall
N (%)
FOBt screening from 2010 to 2012
Yes
2817 (71%)
No
1158 (29%)
p value
Perceived life expectancy
Low (0 to 24%) 243 (6%) 126 (5%) 117 (10%) <0.0001
Lower middle (25 to 49%) 312 (8%) 197 (7%) 115 (10%)
Higher middle (50 to 74%) 1737 (44%) 1222 (43%) 515 (45%)
High (75 to 100%) 1683 (42%) 1272 (45%) 411 (35%)
Age
Mean SD 62.6 (4.1) 62.3 (3.9) 63.1 (4.6) <0.0001
Sex
Male 1801 (45%) 1238 (44%) 563 (49%) 0.007
Female 2174 (55%) 1579 (56%) 595 (51%)
Educational attainment
Post-secondary degree equivalent 1152 (29%) 851 (30%) 301 (26%) <0.0001
Up to a post-secondary degree 1938 (49%) 1417 (50%) 521 (45%)
No qualifications 885 (22%) 549 (20%) 336 (29%)
Ethnicity
White 3887 (98%) 2760 (98%) 1127 (97%) 0.21
Non-white 88 (2%) 57 (2%) 31 (3%)
Marital status
Married or living as married 3071 (77%) 2249 (80%) 822 (71%) <0.0001
Single 904 (23%) 568 (20%) 336 (29%)
Smoking status
Never smoker 1574 (40%) 1175 (42%) 399 (34%) <0.0001
Former smoker 1850 (47%) 1335 (47%) 515 (44%)
Current smoker 551 (14%) 307 (11%) 244 (22%)
Age of mother currently or at death
Mean (SD) 78 (12) 78 (12) 77 (13) 0.03
Age of father currently or at death
Mean (SD) 72 (13) 73 (13) 71 (14) 0.002
Numeracy score
Mean (SD) 4.4 (1.2) 4.5 (1.2) 4.2 (1.3) <0.0001
Self-reported general health
Excellent 571 (14%) 426 (15%) 145 (13%) <0.0001
Very good 1311 (33%) 989 (35%) 322 (28%)
Good 1248 (31%) 889 (32%) 359 (31%)
Fair 652 (16%) 413 (15%) 239 (21%)
Poor 193 (5%) 100 (3%) 93 (8%)
Cancer
No 3699 (93%) 2630 (94%) 1069 (92%) 0.24
Yes 276 (7%) 187 (6%) 89 (8%)
Cardiovascular disease
No 3044 (77%) 2193 (78%) 851 (73%) 0.003
Yes 931 (23%) 624 (22%) 307 (27%)
High blood pressure
No 2444 (61%) 1765 (63%) 679 (59%) 0.02
Yes 1531 (39%) 1052 (37%) 479 (41%)
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Discussion
In this population-based cohort study of English men and
women who were age-eligible for nationally organized
FOBt-based CRC screening, perceived life expectancy at
baseline was a strong positive predictor of FOBt uptake over
the 4-year study follow-up. Three quarters of men and women
who rated their chances of living another 10 to 15 years as 75–
100% at baseline completed at least one FOBt over the follow-
up, compared to half of those who rated their chances as 0–
24%. This finding was independent of sociodemographic fac-
tors, numeracy skills, self-rated health, and other risk factors
for mortality, including smoking status and chronic disease
diagnoses. It was also independent of score on a validated
Table 2 Logistic regression
models predicting FOBt
screening, The English
Longitudinal Study of Ageing,
2008–13, n = 3975
Unadjusted OR
(95% CI)
Adjusted OR 1a
(95% CI)
Adjusted OR 2a
(95% CI)
Perceived life expectancy
Low (0 to 24%) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Lower middle (25 to 49%) 1.59 (1.13, 2.24) 1.32 (0.93, 1.88) 1.33 (0.93, 1.88)
Higher middle (50 to 74%) 2.20 (1.68, 2.89) 1.52 (1.14, 2.03) 1.57 (1.18, 2.08)
High (75 to 100%) 2.87 (2.18, 3.78) 1.74 (1.29, 2.34) 1.81 (1.35, 2.43)
Age
Per year 0.95 (0.94, 0.97) 0.96 (0.95, 0.98) –
Sex
Male 1.00 (ref) 1.00 (ref) –
Female 1.20 (1.05, 1.38) 1.30 (1.12, 1.51) –
Educational attainment
Post-secondary degree or equivalent 1.00 (ref) 1.00 (ref) 1.00 (ref)
Up to a post-secondary degree 0.96 (0.82, 1.14) 1.04 (0.88, 1.23) 1.03 (0.87, 1.22)
No qualifications 0.58 (0.48, 0.70) 0.79 (0.64, 0.98) 0.79 (0.64, 0.97)
Ethnicity
White 1.00 (ref) 1.00 (ref) 1.00 (ref)
Non-white 0.75 (0.48, 1.17) 0.83 (0.52, 1.32) 0.85 (0.53, 1.35)
Marital status
Married or living as married 1.00 (ref) 1.00 (ref) 1.00 (ref)
Single 0.62 (0.53, 0.72) 0.72 (0.61, 0.84) 0.71 (0.60, 0.83)
Smoking status
Never smoker 1.00 (ref) 1.00 (ref) –
Former smoker 0.88 (0.76, 1.03) 0.94 (0.81, 1.10) –
Current smoker 0.43 (0.35, 0.52) 0.52 (0.42, 0.65) –
Age of mother currently or at death
Per 10 years 1.06 (1.01, 1.12) 1.00 (0.95, 1.06) 1.01 (0.95, 1.07)
Age of father currently or at death
Per 10 years 1.08 (1.03, 1.14) 1.04 (0.98, 1.10) 1.04 (0.99, 1.10)
Numeracy score
Per 1 point (out of 6) 1.16 (1.10, 1.23) 1.06 (1.00, 1.13) 1.05 (0.99, 1.12)
Self-reported general health
Excellent 1.00 (ref) 1.00 (ref) 1.00 (ref)
Very good 1.05 (0.83, 1.31) 1.12 (0.89, 1.41) 1.12 (0.89, 1.41)
Good 0.84 (0.67, 1.06) 0.99 (0.79, 1.26) 1.02 (0.81, 1.29)
Fair 0.59 (0.46, 0.75) 0.86 (0.66, 1.13) 0.93 (0.71, 1.21)
Poor 0.37 (0.26, 0.51) 0.64 (0.44, 0.92) 0.75 (0.51, 1.08)
Cancer
No 1.00 (ref) 1.00 (ref) –
Yes 0.85 (0.66, 1.11) 0.90 (0.68, 1.19) –
Cardiovascular disease
No 1.00 (ref) 1.00 (ref) –
Yes 0.79 (0.67, 0.92) 1.00 (0.84, 1.19) –
High blood pressure
No 1.00 (ref) 1.00 (ref) –
Yes 0.84 (0.73, 0.97) 0.98 (0.84, 1.14) –
ELSA Mortality Risk Index scoreb
Per 1 point (out of 11) 0.87 (0.84, 0.89) – 0.91 (0.88, 0.94)
a Adjusted for all variables in the column
b ELSA Mortality Risk Index scores include age, sex, comorbid conditions (cancer, lung disease, and heart
failure), smoking status, level of physical activity, and difficulty with functional tasks (preparing a hot meal,
walking 100 yards, and pushing and pulling large objects). Scores ranged from 1 to 18 points, but are collapsed at
11 points
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index of 10-year mortality risk for older adults, indicating that
perceived and objectively estimatedmortality riskmight make
unique contributions to predicting CRC screening behavior.
Our finding has particular salience for two issues in CRC
screening: the fact that CRC screening is not recommended
for adults with an actual life expectancy of less than 10 years,
and persistent socioeconomic inequalities in CRC screening
uptake.
Based on increasing evidence for the lack of benefit of
CRC screening in older adults with a low life expectancy,
the American College of Physicians does not recommend
screening in adults with less than 10 years of remaining actual
life expectancy [12]. In this group, the benefits of early diag-
nosis are minimal and considered to be outweighed by the
potential harms of screening including unnecessary diagnostic
procedures and overtreatment. In the USA, recent studies have
found that participation in cancer screening is common among
this group [20–22], sparking the development of strategies to
tailor screening guidelines to account for differential life ex-
pectancies within age strata [23, 24]. Uptake of screening
among adults with low life expectancy is thought to occur
partly because there is generally high public enthusiasm for
cancer screening at older ages and also because the contrain-
dication of screening can be difficult for physicians to com-
municate to patients with high mortality risk [25–28].
Information about the time frame that elapses before screening
confers a mortality benefit is not communicated to the public
as part of the screening invitations in the UK, and it does
currently not form part of the guidelines for CRC screening
given by the US Centers for Disease Control and Prevention,
the US Preventive Services Task Force, or the American
Cancer Society [28–30].
Better public communication about the aims of screening
may help to optimize uptake, as our study indicates that people
may take into account their expectations of the future when
making decisions about screening. This is good news, al-
though a substantial proportion of adults who perceived their
own life expectancy as low—less than a 25% chance of living
another 10–15 years—still participated in CRC screening.
Assuming a reasonable level of accuracy in their life expec-
tancy estimations, the reasons why these adults complete
screening despite their low expectations of future survival
require further investigation. Conversely, many people with
high expectations of their future survival did not complete
CRC screening and consequently may be missing out on the
benefits of screening intended for this group. These findings
are concerning, as PLE showed good concordance with ob-
jectively estimated 10-year mortality risk in this study and was
predictive of actual mortality risk in a national sample of older
American adults. In the HRS, older adults who survived over
a 2-year follow-up had, on average, a 50-point higher estimate
of 15–25-year PLE than those who died [10]. In a longer 8-
year follow-up, those who died reported a 56% chance of 15–
25-year survival at baseline, on average, compared with a
65% average chance reported by those who survived [11].
The potential impact of life expectancy perceptions on so-
cioeconomic inequalities in CRC screening uptake is also im-
portant to consider. Inequalities in screening uptake based on
several socioeconomic indicators have been demonstrated in
several country contexts [31, 32]. Adults with low educational
attainment and who have experienced economic hardship
have, on average, lower expectations for their remaining life
expectancy than those who are better off [33]. Having higher
perceived life expectancy is thought to increase one’s sense of
control over their own life and events in the future (the “hori-
zon hypothesis”) [34], which could in turn increase the likeli-
hood of participating in cancer screening [35]. Low percep-
tions of personal life expectancy, if more frequent among
adults of low socioeconomic status, might have the adverse
effect of contributing to inequalities in CRC screening uptake
and eventually to cancer outcomes, including mortality.
Further work is needed to examine the accuracy of life expec-
tancy perceptions across socioeconomic groups, in order to
establish the degree to which lowered expectations of the fu-
ture may present a barrier to cancer screening that could be
targeted and modified by public communication strategies.
Our results are consistent with those from the European
SHARE study, which found that PLE was positively associ-
ated with mammography uptake in women [13]. In our study,
“ever” FOBt uptake over the follow-up from 2010 to
2012/2013 was 71%, consistent with NHS records for ever
uptake of 70.1% in the general eligible population of over
60,000 men and women in the southern region of England
over a similar time period [36]. Overall, uptake was negatively
associated with age in our study. When screening was initially
available to 60–69-year-olds from 2006 to 2010, age was pos-
itively associated with uptake, likely because older adults
would have received more biennial screening invitations than
younger adults within this age range [36]. Adults aged 70–
74 years were then invited from 2010 as part of an age
Table 3 PLE according
to the ELSA Index for
10-year mortality risk
ELSA Index
point score
Number Mean
PLE (SD)
1 239 73.6 (17.9)
2 299 71.4 (17.8)
3 608 71.4 (19.8)
4 568 67.8 (21.3)
5 626 67.5 (20.7)
6 585 64.0 (22.0)
7 432 62.2 (24.9)
8 298 57.4 (24.4)
9 132 52.4 (26.9)
10 110 52.8 (27.2)
≥11 78 43.7 (28.0)
ann. behav. med. (2017) 51:327–336 333
extension. In the period from 2006 to 2012, NHS records
show that uptake peaks in the middle of the 60–74 age range
[36]. Our results also show this trend when broken down by
age at follow-up, with uptake at 64% among 60-year-olds,
75% among 69-year-olds, and 50% among 74-year-olds.
Our results for the other predictors of FOBt uptake, which
were being female, having higher education, being married,
not smoking, having better numeracy skills, and better self-
rated health, are consistent with previous research [31, 32,
36–39].
A limitation of this study is that FOBt uptake was assessed
through self-report. However, uptake rates were consistent
with those observed in the general screening-eligible popula-
tion over a similar time period [36]. Self-reported screening
uptake in a similar sample, in the context of England’s NHS
Bowel Cancer Screening Programme, was recently highly
concordant with NHS records (94.2% agreement, κ = 0.74)
[15]. History of colonoscopy or sigmoidoscopy or completion
of a physician-recommended FOBt was not assessed in the
study interview. These scenarios, respectively, would have
made participants ineligible for the program ormay have over-
ridden any effects of PLE on screening behavior. We expect
that this would apply to the minority of study participants. We
did not have data on the total number of FOBt screening kits
that a person had completed in the past. Some people in the
sample may have completed screening prior to the study pe-
riod, as the screening programwas implemented in small areas
in 2006 and rolled out nationwide during the period 2006 to
2010 [40]. The reverse relationship of screening participation
on PLE is uncertain and may depend on the time elapsed
between a screening episode and the PLE assessment. The
PLE estimates in this study may represent, to a degree, the
aggregate of health-related behaviors and events that people
experienced over their lives. When considered in this way,
there may be bidirectional relationships between PLE and
health-related behaviors, a question that requires further
investigation.
Although the ELSA aims to be population-representative,
it is subject to non-response and attrition bias, as with any
longitudinal cohort study. Compared with participants who
remained in the study, those who dropped out between waves
4 and 6 had lower educational attainment, were more socio-
economically deprived, and were in worse health (self-rated
and diagnoses of cardiovascular disease and cancer). They
were underrepresented in this analysis. Mean PLE was also
lower among those who dropped out of the study than those
who remained in the study (51.4%, SD 30.9 vs. 59.9%, SD
26.6%; p < 0.0001). Consequently, if those who dropped out
were less likely to have participated in FOBt screening than
those who remained in, we may have underestimated the true
association between PLE and screening uptake. Only 2% of
participants were non-white, so we did not have adequate
statistical power to examine the role of ethnicity.
Measurement error may have been introduced if partici-
pants’ PLE estimates changed between the study baseline
and the actual time of cancer screening. If this occurred and
was non-differential across the study population, then odds
ratios for PLE and FOBt screening will be biased towards
the null, underestimating the magnitude of the true associa-
tion. If certain subgroups were more likely to decrease or
increase in PLE than others, the odds ratios may be biased
downwards or upwards. If PLE estimates were relatively ac-
curate, then they would, to a degree, represent the same un-
derlying construct as objectively estimated mortality risk (i.e.,
actual mortality risk). The PLE estimates showed good con-
cordance with 10-year mortality risk according to the validat-
ed and reliable ELSA Mortality Risk Index [17]. While our
results indicate that there is overlap between self-perceived
and objectively estimated mortality risk, they predicted
FOBt uptake independently of one another, indicating that
they might make unique contributions to predicting behavior.
We hypothesize that inaccuracies in PLE estimates would be
greatest among those older adults with low educational attain-
ment, low socioeconomic status, or poor literacy or numeracy
skills or who have experienced aging-related cognitive de-
cline. Further work with follow-up mortality data is needed
to identify which adults had incorrectly low or high percep-
tions of their remaining life expectancy. The two scenarios
may have different implications for cancer screening and po-
tentially other health behaviors as well. This is an important
area for future work.
In summary, this is the first longitudinal analysis of per-
ceived life expectancy and CRC screening uptake in the con-
text of an organized, publicly available screening program.
We found that men and women who rated their chance of
living another 10 to 15 years as 75–100% at baseline were
significantly more likely to complete at least one FOBt for
CRC screening than those who rated their chance as 0–25%.
A substantial proportion of adults with low expectations of
survival participated in CRC screening, despite this screening
test not being recommended for adults with low remaining life
expectancy. If PLE estimations are reasonably accurate among
this group, they might be subject to greater harm than benefit
from screening. At the same time, one quarter of adults with
high expectations of their own life expectancy appeared to be
missing out on the benefits of screening intended for this
group. It appears that CRC screening may not be optimized
to the greatest possible benefit for either group. A better un-
derstanding of how people develop their mental models of
PLE might help identify those who are at risk of overly fatal-
istic attitudes towards their futures and potentially at risk of
declining important health services such as cancer screening.
While we do not recommend that PLE be used as a basis
for decision making about screening, further research should
investigate whether public communication about the role of
actual life expectancy in conferring the benefits of cancer
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screening might help to improve decision making. Any poten-
tial communication strategies would have to be carefully de-
signed and implemented to avoid any public misunderstand-
ing. Mortality risk calculators that are validated, accurate, and
suitably brief could be useful tools to aid in shared clinical
decision making with respect to cancer screening, although
their potential to foster fatalistic attitudes about life expectan-
cy must be carefully considered. Finally, if the accuracy of life
expectancy perceptions differs across population subgroups,
the implications of public communication for social equity in
uptake of screening will require careful consideration.
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